scholarly journals Extreme growth factor signalling can promote oestrogen receptor-α loss: therapeutic implications in breast cancer

2004 ◽  
Vol 6 (4) ◽  
Author(s):  
Julia MW Gee ◽  
Martin G Giles ◽  
Robert I Nicholson
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Oestrogen Receptor ◽  
Therapeutic Implications ◽  
Growth Factor Signalling ◽  
Oestrogen Receptor Α

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer

2005 ◽  
Vol 12 (Supplement_1) ◽  
pp. S29-S36 ◽  
Author(s):  
R I Nicholson ◽  
I R Hutcheson ◽  
S E Hiscox ◽  
J M Knowlden ◽  
M Giles ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Oestrogen Receptor ◽  
De Novo ◽  
Acquired Resistance ◽  
Endocrine Resistance ◽  
Breast Cancer Patients ◽  
Selective Oestrogen Receptor Modulators ◽  
Growth Factor Signalling

De novo insensitivity and acquired resistance to the selective oestrogen receptor modulator tamoxifen and the pure anti-oestrogen fulvestrant (faslodex) severely limit their effectiveness in breast cancer patients. This is a major clinical problem, since each year upward of 1 million women are dispensed anti-oestrogenic drugs. In order to investigate the phenomenon of anti-oestrogen resistance and to rapidly screen drugs that target the resistance mechanism(s), we have previously established several in vitro breast cancer models that have acquired resistance to anti-hormones. Such cells commonly develop an ability to proliferate after approximately 3 months of exposure to 4-hydroxytamoxifen or fulvestrant, despite an initial endocrine-responsive (i.e. growth-suppressive) phase. The current paper explores the role that growth factor signalling plays in the transition of oestrogen receptor-positive endocrine-responsive breast cancer cells to anti-oestrogen resistance or insensitivity and how we might, in the future, most effectively use anti-growth factor therapies to treat or delay endocrine-resistant states.

Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies

2005 ◽  
Vol 93 (2-5) ◽  
pp. 257-262 ◽  
Author(s):  
R.I. Nicholson ◽  
I.R. Hutcheson ◽  
D. Britton ◽  
J.M. Knowlden ◽  
H.E. Jones ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Therapeutic Strategies ◽  
Growth Factor Signalling
Sign in / Sign up

Export Citation Format

Share Document